Home / Glenn Flux

Glenn Flux

October 13, 2021

The contribution of hybrid imaging to radionuclide therapy

Radionuclide therapy is a rapidly evolving field considered a safe and effective targeted approach to treating many types of cancer. Radiation is systemically or locally delivered using pharmaceuticals that either bind preferentially to cancer cells or accumulate at the site of treatment by physiological mechanisms. Almost all radionuclides used in radionuclide therapy emit photons that […]

Carla Aberu, Paul Gape, Jan Taprogge, Glen Fluxx

The Royal Marsden Hospital, The Institute of Cancer Research

Read Article

June 16, 2021

The future of molecular radiotherapy

Molecular radiotherapy (MRT) refers to treatment that delivers radiation to a tissue via the interaction of a radiopharmaceutical with a molecular receptor, although is used in a more general sense to refer to any treatment with radiotherapeutics that can take account of imaging and patient dosimetry. Probably the most well-known example of MRT is the […]

Professor Jon Wadsley, Dr Glenn Flux

Weston Park Cancer Centre, Royal Marsden Hospital

Read Article

August 14, 2018

The changing landscape of molecular radiotherapy

Radionuclide therapy is probably the only field of medicine that allows direct imaging of a drug as it is used to treat cancer. Radioiodine was first used over 70 years ago for the treatment of benign thyroid disease and thyroid cancer. Levels of activity to administer were determined empirically, influenced largely by limitations in supply […]